Table 1.

Osteosarcoma PDX model response to eltrombopag.

Model	aKM med (days)	bEFS T - C (days)	cEFS T/C	dp-value Gehan-Wilcoxon	eminRTV mean ± SD	fminRTV p-value	Objective Response Measure
5 mg/kg
OS-2	26.0	0.9	1.03	p = 0.172	1.134 ± 0.091	p = 0.631	PD1
OS-9	23.0	1.5	1.07	p = 0.881	1.686 ± 0.461	p = 0.739	PD1
OS-31	16.1	0.6	1.04	p = 0.407	1.774 ± 0.188	p = 0.011	PD1
OS-33	21.1	2.2	1.12	p = 0.109	1.472 ± 0.236	p = 0.123	PD1
OS-36	18.1	2.8	1.18	p = 0.170	2.019 ± 0.352	p = 0.684	PD1
OS-60-SJ	34.1	0.0	1.00	p = 0.452	1.228 ± 0.113	p = 0.353	PD1
50 mg/kg
OS-2	24.9	3.7	1.2	p = 0.015	1.403 ± 0.241	p = 0.529	PD1
OS-9	20.5	3.8	1.2	p = 0.014	1.752 ± 0.197	p = 0.143	PD1

^aKaplan–Meier estimate of median days to event;

^bEFS (event-free survival) T-C is the median time to event of the treated group minus the median time to event of the control groups;

^cEFS (event-free survival) T/C is the ratio of the median time to event between treated and control groups;

^dP-values comparing event-free survival between the treated and control groups;

^eminRTV (minimum relative tumor volume);

^fP-values comparing the minRTV between the treated and control groups, P-value <0.05 is considered statistically significant.